Drugs / Rizedisben
Rizedisben
also known as
GE-3126 · Illuminare-1 · Illuminare-1 hydrochloride · RIZEDISBEN HYDROCHLORIDE · Rizedisbene
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04983862 | Oct 2021 → Sep 2025 | prostate adenocarcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rizedisben | “Rizedisben is a myelin-binding fluorophore that fluoresces in the blue light (370-425 nm) spectrum to improve intraoperative nerve identification.” PMID 40601345 ↗ Aug 2025 |
| Known as | GE-3126 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314483 ↗ |
| Known as | Illuminare-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314483 ↗ |
| Known as | Illuminare-1 hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314483 ↗ |
| Known as | RIZEDISBEN HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314483 ↗ |
| Known as | Rizedisbene | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314483 ↗ |
| Modality | Small molecule | — CHEMBL5314483 ↗ |
| Route | Intravenous | “Rizedisben was intravenously administered intraoperatively 30 minutes prior to visualization of the obturator nerve.” PMID 40601345 ↗ Aug 2025 |